NCT07255885Completed
CRYSTALSIGHT: ''Cohort 1.5" Clinical Investigation Study With OCCUTRACK and Tan Tock Seng Eye Clinic to Further Develop Remote Monitoring of Maculopathy at Home Using Artificial Intelligence for Eye Tracking
Source: ClinicalTrials.gov · Last updated 8 Jan 2026
Brief summary (registry, in English)
The development of a next-generation 'CRYSTALSIGHT' solution using combinations of a novel and cost-effective eye-tracking system with artificial intelligence-based eye-tracking algorithms that detect macular abnormalities and enable clinicians to review and monitor the prognosis of patients via a web platform through the following deliverables. 1. Evaluate and improve a home-monitoring regimen involving the self-tests of the CRYSTALSIGHT gaze-tracking system 2. To demonstrate that CRYSTALSIGHT has the same or superior gaze-tracking capacities as Tobii. 3. Evaluate the CRYSTALSIGHT device for its functionality and ease of use as a qualitative measurement tool for patients. 4. Develop the Design History File (DHF) for regulatory filing requirements. 2\. This study will improve on the existing gaze-based scoring methodology for disease activity monitoring over time (delta-change) by quantitatively measuring saccadic speed, pursuit and micro-saccades.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 20 (actual)
- First submitted
- 17 Mar 2025
- Start date
- 8 May 2025
- Primary completion date
- 31 May 2025
- Lead sponsor
- Tan Tock Seng Hospital
- Diseases
- Macular degeneration, Diabetic eye disease
- NCT number
- NCT07255885
What you commit to
- Study type: Observational
- Participants enrolled: 20
- From 8 May 2025 to the primary completion date, 31 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could either reduce the potential for visual improvement or require medical or surgical intervention during the study.
Other illness
- History of idiopathic or autoimmune-associated uveitis in either eye.
- Active ocular inflammation or suspected or active ocular or periocular infection in either eye.
- Individuals with indications of cognitive impairment and unable to make decisions for themselves to provide informed consent will be excluded from the study.
Other
- Uncontrolled blood pressure, defined as systolic blood pressure \>180 millimeters of mercury (mmHg) and/or diastolic blood pressure \>100 mmHg while a patient is at rest.
- Other protocol-specified exclusion criteria may apply.
Who the study is looking for
- Participants between ages 21 and 100
- Both genders
- Subjects with maculopathies
- Ability to comply with the study protocol, in the investigator's judgment
- Subjects must have the cognitive capacity to provide personal consent (i.e. no cognitively impaired persons will be recruited).
Age in the registry: 21 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tan Tock Seng Hospital Coordinator of this site? Confirm its status | Singapore | Singapore | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.